Bladder cancer is the sixth-most prevalent cancer in North America and has a recurrence rate greater than 50%, making it the most expensive cancer to treat. All-in costs in the US are around $4 billion and roughly 80,000 new American cases are reported each year, with 350,000 cases internationally.

Targeting bladder cancer is Imagin Medical Inc., a bio-medical research and development Company developing a new method to visualize cancer through minimally invasive surgery that could drastically improve the means by which physicians can visualize the surgical field and detect cancer The company’s initial target is bladder cancer.

Trading on the Canadian Securities Exchange under the symbol IME, the Company’s i/Blue Imaging System uses proprietary optics and light sensors to combine blue and white light with an FDA-approved drug to significantly increase the efficiency and accuracy of detecting cancer. 

 We are joined by Imagin’s Chief Executive Officer, Jim Hutchens to learn more about this Company’s work ....